Isoxsuprine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hydrochloride

# Isoxsuprine hydrochloride ## Overview Isoxsuprine hydrochloride is a vasodilator. Its mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle. It also has some beta-adrenergic agonist activity. ## Primary Indications * Peripheral vascular disease (e.g., arteriosclerosis obliterans, Buerger's disease) to improve blood flow and relieve intermittent claudication. * Vasospasm associated with peripheral vascular disease. ## Adult Dosing * **Peripheral Vascular Disease:** 10 mg to 20 mg orally 3 to 4 times daily. * Maximum daily dose: Not clearly established, but typical dosages rarely exceed 80 mg/day. ## Pediatric Dosing * No established pediatric dosing. Use is generally not recommended in pediatric patients due to lack of data. ## Dose Adjustments * **Renal Impairment:** No specific dosage adjustments are established. Caution is advised as drug accumulation may occur. * **Hepatic Impairment:** No specific dosage adjustments are established. Caution is advised. ## Contraindications * Hypersensitivity to isoxsuprine hydrochloride. * Use in patients with congenital heart disease. * Use in patients who have not had their hypertension controlled. ## Adverse Effects * **Common:** Nausea, vomiting, gastric distress, dizziness, weakness, flushing, hypotension, tachycardia, rash. * **Less Common:** Palpitations, abdominal pain, drowsiness, nervousness. ## Key Drug Interactions * **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive drugs, leading to additive hypotension. Monitor blood pressure closely. * **Epinephrine:** May antagonize the vasodilator effects of isoxsuprine. ## Monitoring * **Blood pressure:** Monitor for hypotension, especially at the initiation of therapy or with dose increases. * **Heart rate:** Monitor for tachycardia. * **Signs and symptoms of peripheral vascular disease:** Assess for improvement in claudication or other symptoms. ## Clinical Pearls * Efficacy in peripheral vascular disease is controversial and not well-supported by robust clinical trial data. * Onset of action may take several weeks. * Administer with food to minimize gastrointestinal upset. *** *This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient safety.*